UBS AM’s Tourmaline Bio TRML Stock Holding History

UBS AM’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,987	Closed	-$621K	–	3334
2025 Q3	$621K	Sell	12,987 -3,916	-23%	-$109K	﹤0.01%	2121
2025 Q2	$270K	Buy	+16,903	New	+$274K	﹤0.01%	2533
2024 Q3	–	Sell	-31,388	Closed	-$404K	–	2855
2024 Q2	$404K	Buy	31,388 +22,488	+253%	+$362K	﹤0.01%	2677
2024 Q1	$204K	Buy	+8,900	New	+$314K	﹤0.01%	2464

UBS AM's TRML Position: Q4 2025 in Review

UBS AM sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 12,987 shares — an estimated $621K sold.

UBS AM first reported a position in TRML in Q1 2024 and held it in 4 quarters. The position peaked at $621K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

UBS AM reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
UBS AM sold 12,987 Tourmaline Bio shares in Q4 2025, an estimated $621K.
UBS AM first reported a position in Tourmaline Bio in Q1 2024 and held it in 4 quarters.
UBS AM's Tourmaline Bio position peaked at $621K in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on UBS AM's 13F filing for Q4 2025, filed 13 Feb 2026.